X-linked sideroblastic anaemia due to ALAS₂ mutations in the Netherlands: a disease in disguise.
BACKGROUND
X-linked sideroblastic anaemia (XLSA; OMIM#300751) is the most common inherited form of sideroblastic anaemia and is associated with several mutations in the erythroid specific 5-aminolevulinate synthase gene (ALAS₂). This gene encodes for aminolevulinic acid synthase 2 (ALAS₂), the catalytic enzyme involved in the first en rate-limiting step of haem biosynthesis.1-3 The disorder is characterised by mostly mild hypochromic microcytic anaemia with bone marrow ring sideroblasts. Even untransfused patients with mild or no anaemia are at risk for severe systemic iron overload due to ineffective erythropoiesis. To date, 61 different ALAS₂ mutations have been reported in 120 families with XLSA. Descriptions of molecularly confirmed case series from the Netherlands, however, are lacking.


METHODS
We reviewed age of presentation, clinical and biochemical features, ALAS₋₂ defects and treatment characteristics of 15 Dutch patients from 11 unrelated families diagnosed with XLSA.


CONCLUSIONS
In one family a novel pathogenic c.1412G>A (p.Cys471Tyr) mutation was found. All other families shared the previously described c.1355G>A (p.Arg452His) mutation. Haplotype analysis in seven probands with the p.Arg452His mutation strongly suggests that six of them were ancestrally related. Nevertheless, their phenotype was very different. Our patients illustrate the phenotypical heterogeneity in the presentation of XLSA patients, the effectiveness of treatment regimens and the various pitfalls associated with the diagnosis, follow-up and treatment of the disease. A timely diagnosis avoids unnecessary investigations and allows adequate treatment that can prevent systemic iron load with subsequent severe life-threatening complications. Therefore, we suggest considering XLSA in both male and female patients with unexplained iron overload and÷or (mild) microcytic anaemia, also at older age.
Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands.
A E
AE
Donker
R A
RA
Raymakers
H K
HK
Nieuwenhuis
M J H
MJ
Coenen
M C
MC
Janssen
M A
MA
MacKenzie
P P T
PP
Brons
D W
DW
Swinkels
D000624:5-Aminolevulinate Synthetase / Q000235:genetics*; D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D000756:Anemia, Sideroblastic / Q000097:blood / Q000453:epidemiology* / Q000235:genetics*; D016644:Canthaxanthin; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D004909:Erythrocyte Indices; D005260:Female; D005293:Ferritins / Q000097:blood; D040181:Genetic Diseases, X-Linked / Q000097:blood / Q000453:epidemiology* / Q000235:genetics*; D005838:Genotype; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009426:Netherlands / Q000453:epidemiology; D011736:Pyridoxine / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000627:therapeutic use; D055815:Young Adult; D019207:beta Carotene
D004338:Drug Combinations; D006454:Hemoglobins; D019207:beta Carotene; D014803:Vitamin B Complex; D016644:Canthaxanthin; C041347:phenoro; D005293:Ferritins; D000624:5-Aminolevulinate Synthetase; C480079:ALAS2 protein, human; D011736:Pyridoxine